<DOC>
	<DOC>NCT00306644</DOC>
	<brief_summary>The study investigated the effect of rosiglitazone and placebo on carotid intima media thickness in patients with insulin resistance syndrome and/or type 2 diabetes.</brief_summary>
	<brief_title>Effect Of Rosiglitazone On Carotid Intima Media Thickness In Patients With Insulin Resistance Syndrome And/Or Type 2 Diabetes</brief_title>
	<detailed_description>RAS Rosiglitazone and Atherosclerosis Study: A 1 year randomised, double-blind, parallel group, placebo controlled study to evaluate the efficacy of rosiglitazone on the progression of intima-media thickness in the carotid artery in subjects with insulin resistance syndrome and/or type 2 diabetes mellitus</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Inclusion criteria: insulin resistant syndrome or Type 2 Diabetes. Exclusion criteria: Use of &gt;= 2 concomitant oral antihyperglycaemic agents within 3 months of study start. Initiation of antihypertensive or lipid lowering therapy &lt;= 6 months prior to study start or who increased the dose 3 months prior to study start. Unstable or severe angina or congestive heart failure NYHA class iiv, history of acute myocardial infarction or stroke within last 6 months. Any history of surgical intervention in the right carotid artery. Clinically significant hepatic disease. Creatinine clearance &lt;40ml/min.</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>rosiglitazone</keyword>
	<keyword>Type 2 diabetes</keyword>
	<keyword>intima media thickness</keyword>
	<keyword>Insulin resistance</keyword>
</DOC>